EE200000510A - CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks - Google Patents

CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks

Info

Publication number
EE200000510A
EE200000510A EEP200000510A EEP200000510A EE200000510A EE 200000510 A EE200000510 A EE 200000510A EE P200000510 A EEP200000510 A EE P200000510A EE P200000510 A EEP200000510 A EE P200000510A EE 200000510 A EE200000510 A EE 200000510A
Authority
EE
Estonia
Prior art keywords
monocyte proliferation
promote peripheral
peripheral monocyte
proliferation
utilization
Prior art date
Application number
EEP200000510A
Other languages
English (en)
Estonian (et)
Inventor
Schwarz Herbert
Langstein Joachim
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Publication of EE200000510A publication Critical patent/EE200000510A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
EEP200000510A 1998-07-15 1999-03-05 CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks EE200000510A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98103859 1998-07-15
PCT/EP1999/001440 WO1999044629A2 (de) 1998-03-05 1999-03-05 Verwendung von cd137 zur förderung der proliferation peripherer monocyten

Publications (1)

Publication Number Publication Date
EE200000510A true EE200000510A (et) 2002-02-15

Family

ID=8231533

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000510A EE200000510A (et) 1998-07-15 1999-03-05 CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks

Country Status (21)

Country Link
US (1) US6627200B1 (cs)
EP (1) EP1059931B1 (cs)
JP (1) JP2003521439A (cs)
KR (1) KR20010041624A (cs)
AT (1) ATE228371T1 (cs)
AU (1) AU747063B2 (cs)
BR (1) BR9908518A (cs)
CA (1) CA2322684A1 (cs)
CZ (1) CZ20003238A3 (cs)
DE (1) DE59903541D1 (cs)
DK (1) DK1059931T3 (cs)
EE (1) EE200000510A (cs)
ES (1) ES2188140T3 (cs)
HU (1) HUP0102046A3 (cs)
IS (1) IS1986B (cs)
NO (1) NO20004393L (cs)
NZ (1) NZ506695A (cs)
PL (1) PL343427A1 (cs)
PT (1) PT1059931E (cs)
SI (1) SI1059931T1 (cs)
WO (1) WO1999044629A2 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232896A1 (en) * 2001-10-04 2005-10-20 Herbert Schwarz Cd137 as a proliferation factor for hematopoietic stem cells
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US20060121030A1 (en) * 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5861191B2 (ja) * 2010-09-30 2016-02-16 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
EP2981334A4 (en) * 2013-04-03 2016-11-23 Univ California COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145499A (ja) * 1989-10-31 1991-06-20 Nippon Kosei Butsushitsu Gakujiyutsu Kiyougikai ヒト単球成長因子
DE4222980A1 (de) 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
AU6827094A (en) * 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
WO1995007984A1 (en) * 1993-09-16 1995-03-23 Indiana University Foundation Human receptor h4-1bb
CA2108401A1 (en) * 1993-09-27 1995-03-28 The Regents Of The University Of California Receptor induced by lymphocyte activation in imflammatory response

Also Published As

Publication number Publication date
IS1986B (is) 2005-02-15
CA2322684A1 (en) 1999-09-10
DE59903541D1 (de) 2003-01-09
ATE228371T1 (de) 2002-12-15
PT1059931E (pt) 2003-04-30
HUP0102046A2 (hu) 2001-10-28
CZ20003238A3 (cs) 2001-10-17
EP1059931A2 (de) 2000-12-20
EP1059931B1 (de) 2002-11-27
NO20004393L (no) 2000-10-31
DK1059931T3 (da) 2003-03-24
ES2188140T3 (es) 2003-06-16
WO1999044629A2 (de) 1999-09-10
IS5613A (is) 2000-08-30
JP2003521439A (ja) 2003-07-15
KR20010041624A (ko) 2001-05-25
US6627200B1 (en) 2003-09-30
HUP0102046A3 (en) 2006-02-28
AU2932499A (en) 1999-09-20
PL343427A1 (en) 2001-08-13
AU747063B2 (en) 2002-05-09
NZ506695A (en) 2005-01-28
WO1999044629A3 (de) 2000-01-06
BR9908518A (pt) 2000-11-21
NO20004393D0 (no) 2000-09-04
SI1059931T1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
DE60014966D1 (de) Behandlung zur vermeidung von kalzifizierung für fixierte biomaterialien
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
ATE413386T1 (de) Ppar-gamma modulatoren
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE69716525D1 (de) Handgelenkstütze zur Behandlung des Karpaltunnelsyndroms
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
PT1169370E (pt) Solucoes de poliuretano contendo unidades estruturais de alcoxissilano.
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
GB9924957D0 (en) Novel treatment
PT1144365E (pt) Inibidores da adesao de celulas mediada por alfa4beta1
BR9813778A (pt) Utilização de pelo menos um fucano.
DE69033970D1 (de) Huperzin a analoge verbindungen
DE69811330D1 (de) Reinigungspflaster zur verbesserung des hautzustandes
ATE285177T1 (de) Thiole zur förderung des wachstumsvon hömatopoietischen vorläuferzellen
EE200000510A (et) CD137 kasutamine perifeersete monotsüütide vohamise soodustamiseks
ATE227995T1 (de) Verwendung von pseudopterosin zur förderung der wundheilung
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis